Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Hanmi Semicon Shares Surge After $33 Million SpaceX Investment
SK Hynix Stock Rebounds as AI Memory Chip Demand Fuels Expansion Plans
Woodside Energy Acquires PetroChina’s Browse Stake, Expands Position in Major Australian Gas Project
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids
Exxon Mobil Set to Appoint Alex Volkov as Global Trading Chief
Roku Explores Sale Options as Interest Grows in Streaming and Ad Business
GM and Peak Energy Partner to Advance Sodium-Ion Battery Technology for Grid Storage
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy
OpenAI May Slash AI Service Prices Amid Growing Rivalry With Anthropic
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally
DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion
SpaceX IPO Set for Explosive Debut as Valuation Tops $2.2 Trillion
Coupang Hit With Record $409 Million Fine Over Data Breach Affecting 33 Million Users
Meta Partners With Reliance to Launch First AI-Powered Data Center in India
Frasers Group Launches €2 Billion Hugo Boss Takeover Offer Amid Control Speculation 



